STOCKHOLM, SE / ACCESS Newswire / January 29, 2025 / Vicore Pharma Holding (STO:VICO)Stockholm, January 29, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of ...

Numerous clinical studies have established that angiotensin II receptor blockers are effective as antihypertensive therapy and are well tolerated. Studies demonstrate that adding an angiotensin II ...

Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...

Several ASX-listed companies are making significant strides in their phase III clinical trials, the critical final stage ...

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

Masaaki Tamura, age 75, passed away surrounded by family at the University of Kansas Medical Center, Kansas City, KS, on Thursday, January 16, 2025, following a sudden illness.

"I wanted to create a simple and cost-effective way to prevent scratches on the lenses of various optical products," said an inventor, from Simi Valley, Calif., "so I invented the EYEWEAR SCREEN ...

A recent study suggests that a commonly prescribed type of blood pressure medication, known as angiotensin receptor blockers ...

In contrast to IL-6, the effects of CNTF on the vasculature have not been explored. Here, we examined the role of CNTF in AngII (angiotensin II)-induced hypertension. Hypertension was chronically ...